Response to "DPYD genotyping panels: Impact of population diversity"
Clin Transl Sci
.
2024 Apr;17(4):e13806.
doi: 10.1111/cts.13806.
Authors
Andrea Gaedigk
1
,
Amy J Turner
2
,
Cyrine E Haidar
3
,
Philip E Empey
4
,
Steven M Offer
5
Affiliations
1
Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA.
2
RPRD Diagnostics LLC, Milwaukee, Wisconsin, USA.
3
Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
4
Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
5
Department of Pathology, University of Iowa, Iowa City, Iowa, USA.
PMID:
38637962
PMCID:
PMC11026573
DOI:
10.1111/cts.13806
No abstract available
Publication types
Letter
MeSH terms
Capecitabine
Fluorouracil*
Genotype
Humans
Substances
Fluorouracil
Capecitabine
Grants and funding
R01 CA251065/CA/NCI NIH HHS/United States